Owing to stalled progress in development of therapeutic targets for AML and reflecting on new advances mapping nucleolar architecture, we identified a clear need to revisit the molecular dynamics of NPM1 in the context of AML. This evidence concerns the gene NPM1 and acute myeloid leukemia.